Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$60.57 USD

60.57
900,429

-1.22 (-1.97%)

Updated Jun 18, 2024 04:00 PM ET

After-Market: $60.69 +0.12 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for CRSP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,694 1,815 2,379 1,690 944
Receivables 200 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 14 38 38 26 44
Total Current Assets 1,908 1,853 2,418 1,717 988
Net Property & Equipment 152 164 138 42 31
Investments & Advances 2 53 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 14 16 22 18 6
Total Assets 2,230 2,243 2,752 1,828 1,067
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 38 27 15 9 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 46 78 92 64 31
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 9 0 1 10 12
Total Current Liabilities 109 121 120 94 57
Mortgages 0 0 0 0 0
Deferred Taxes/Income 14 12 0 12 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 6 20 8 14
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 347 368 352 164 127
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 2 2 2 2
Capital Surplus 2,878 2,735 2,598 2,236 1,162
Retained Earnings -1,000 -846 -196 -574 -225
Other Equity 2 -16 -5 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,883 1,875 2,399 1,664 939
Total Liabilities & Shareholder's Equity 2,230 2,243 2,752 1,828 1,067
Total Common Equity 1,883 1,875 2,399 1,664 939
Shares Outstanding 79.40 78.20 76.50 71.20 55.20
Book Value Per Share 23.71 23.98 31.37 23.37 17.02

Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 2,108 1,694 1,740 1,768 1,883
Receivables 0 200 0 70 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 12 14 21 21 25
Total Current Assets 2,120 1,908 1,761 1,860 1,908
Net Property & Equipment 147 152 156 159 162
Investments & Advances 0 2 0 5 6
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 21 14 14 14 14
Total Assets 2,439 2,230 2,087 2,197 2,244
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 16 38 26 28 45
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 78 46 67 90 86
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 9 9 4 0 0
Total Current Liabilities 119 109 111 133 147
Mortgages 0 0 0 0 0
Deferred Taxes/Income 14 14 16 12 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4 5 5 6
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 355 347 359 381 389
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 2 2 2
Capital Surplus 3,199 2,878 2,821 2,799 2,761
Retained Earnings -1,116 -1,000 -1,089 -977 -899
Other Equity -2 2 -7 -9 -9
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,084 1,883 1,728 1,816 1,855
Total Liabilities & Shareholder's Equity 2,439 2,230 2,087 2,197 2,244
Total Common Equity 2,084 1,883 1,728 1,816 1,855
Shares Outstanding 84.80 79.40 79.40 78.90 78.80
Book Value Per Share 24.57 23.71 21.76 23.02 23.54